TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed high grade serous and/or undifferentiated carcinoma of ovary, fallopian tube or peritoneum~* Oestrogen, progesterone and HER2 negative advanced adenocarcinoma of the breast~* Known BRCA positive breast cancer or ovarian cancer, that is not high grade serous or undifferentiated tubo-ovarian carcinoma.~* Performance status of no more than 2.~Exclusion Criteria:~* Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry~* Major surgery with 4 weeks of entering the study and must have recovered from effects of any major surgery .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Triple negative breast Cancer with unknown BRCA mutation status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral
- 2 (Type: EXPERIMENTAL): Known BRCA mutation positive breast cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) to be administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral
- 3 (Type: EXPERIMENTAL): High grade serous/undifferentiated tubo-ovarian carcinoma with unknown BRCA status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral
- 4 (Type: EXPERIMENTAL): Known BRCA mutation positive ovarian cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally~AZD2281, PARP inhibitor Olaparib tablets, oral

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients ≥ 18 years of age~* An acute onset of at least 3 of the following signs and symptoms (new or worsening):~  1. Cough~ 2. Production of purulent sputum~ 3. Shortness of breath (dyspnea)~ 4. Chest pain due to pneumonia~* At least 1 of the following:~  1. Fever~ 2. Hypothermia~ 3. Presence of pulmonary rales and/or evidence of pulmonary consolidation~* PORT Risk Class II, III, or IV~* Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study~* Not received any systemic antibiotics during the prior 7 days~Exclusion Criteria:~* Ventilator-associated pneumonia~* Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented severe chronic obstructive pulmonary disease~* Hospitalization within 90 days or residence in a long-term care facility within 30 days prior to the onset of symptoms~* Fungal pneumonia~* Pneumocystis jiroveci pneumonia~* Aspiration pneumonia~* Other non-infectious causes of pulmonary infiltrates~* Primary or metastatic lung cancer~* Cystic fibrosis~* Active or suspected tuberculosis~* HIV or myasthenia gravis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Intravenous with the potential step-down to oral moxifloxacin
- Solithromycin (Type: EXPERIMENTAL): Intravenous with potential step-down to oral solithromycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria :~* Participants with T2DM diagnosed at least 1 year before the screening visit.~* Treatment with neutral protamine hagedorn (NPH) or insulin glargine for at least 3 months and at a stable dose (±20%) of at least 10 IU/day (for at least 2 months prior to screening) alone or combined with a stable dose of metformin with or without dipeptidyl peptidase 4 (DPP-4) inhibitor or sulfonylurea.~* Glycosylated hemoglobin (HbA1c) ≥6.5 and ≤9.5%.~* Body mass index (BMI) between 20 and 40 kg/m\^2.~Exclusion criteria:~* Pregnant women or breastfeeding women.~* Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including, but not limited to, gastroparesis and gastroesophageal reflux disease requiring medical treatment within 6 months prior to the time of screening.~* Any previous treatment with lixisenatide or participation in a previous study with lixisenatide (AVE0010), and any previous treatment with liraglutide stopped for safety concern or lack of efficacy.~* Allergic reaction to any glucagon-like peptide-1 (GLP-1) agonist in the past (eg, exenatide) or to metacresol.~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.~* Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Lixisenatide 20 μg (Type: EXPERIMENTAL): Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
- Liraglutide 1.2 mg (Type: ACTIVE_COMPARATOR): Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
- Liraglutide 1.8 mg (Type: ACTIVE_COMPARATOR): Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years~* Type 2 Diabetes Mellitus~* Hemoglobin A1c \< 10%~* Stable diabetes therapy~* Must be on maximally tolerated dose of statin of at least moderate Intensity~* Fasting triglycerides ≤ 600 mg/dL~* Not at LDL-C or Non-HDL-C goal.~Exclusion Criteria:~* Moderate to severe renal dysfunction~* Uncontrolled hypertension~* Persistent active liver disease or hepatic dysfunction~* Has taken a cholesterylester transfer protein inhibitor in the last 12 months,~* Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft or stroke within 3 months prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
- Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with bacterial conjunctivitis in 1 or both eyes;~* Able to understand and sign an informed consent form. If subject is \<18 years of age, the informed consent must be understood and signed by the subject's legally authorized representative;~* Agrees to comply with the visit schedule and other requirements of the study;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to Day 1;~* Presence of concomitant viral infection;~* Infants with ophthalmia neonatorum of gonococcal, Chlamydia, herpetic or chemical origin;~* Infants whose birth mothers had any sexually transmitted disease within 1 month prior to delivery;~* Infants undergoing treatment for retinopathy of prematurity;~* Contact lens wear during the course of the study;~* Only 1 sighted eye or vision in either eye not correctable to 0.6 logMAR units (20/80) or better;~* Use of medications, as specified in the protocol;~* Any systemic or ocular disease or disorder, complicating factors or structural abnormality that could negatively affect the conduct or outcome of the study;~* Known or suspected allergy or hypersensitivity to fluoroquinolones;~* Pregnant, lactating, or of childbearing potential and not using adequate birth control to prevent pregnancy;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin AF (Type: EXPERIMENTAL): Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
- Vehicle (Type: PLACEBO_COMPARATOR): Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have type 1 diabetes mellitus (T1DM) for at least 1 year~* Must have have inadequate glycemic control (as defined by glycosylated hemoglobin level of \>= 7.0% to \<= 9.0%) on basal plus bolus insulin at screening~* Must have body mass index 21 to 35 kg/m2 inclusive~* Must be on a total daily dose of insulin \>= 0.6 IU/kg at screening~* Must be on a stable insulin regimen for at least 8 weeks prior to screening~Exclusion Criteria:~* History of T2DM, pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* Severe hypoglycemia (defined as an event required assistance from another person, or which resulted in seizure or loss of consciousness) within 6 months prior to study start~* Diabetic ketoacidosis within 6 months prior to study start~* History of hereditary glucose-galactose malabsorption or primary renal glycosuria~* An ongoing, inadequately controlled thyroid disorder

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will receive matching placebo once daily for 18 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Healthy infants able to attend all study visits~* Parent(s)/legal representative able to read, understand, and complete study questionnaires~Exclusion Criteria~* History of congenital or acquired immunodeficiency~* Received or is expected to receive immunosuppressive agents or systemic immunomodulatory steroids~* History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disorder~* Hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines or concomitant study vaccines~* Has any chronic illness that could interfere with study conduct or completion~* Received any immune globulin, blood, or blood-derived products since birth~* Received a dose of hepatitis B vaccine prior to the study~* Vaccinated with any acellular pertussis or whole cell pertussis based combination vaccines, Haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate or pneumococcal polysaccharide, rotavirus, measles, mumps, rubella, or varicella vaccines, or any combination thereof~* Fever within 24 hours prior to enrollment~* Received any non-study vaccine within 30 days prior to enrollment, except for inactivated influenza vaccine, which is permitted 14 days or more prior to enrollment~* Has a coagulation disorder~* Has developmental delay or neurological disorder~* Participant or his/her mother has a medical history of hepatitis B surface antigen (HBsAg) seropositivity~* History of measles, mumps, rubella, varicella, Haemophilus influenzae type B, hepatitis B, diphtheria, tetanus, pertussis, rotavirus, invasive pneumococcal, or poliomyelitis infection

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 74 Days
- Healthy Volunteers: t

Study Arms:
- PR5I (Type: EXPERIMENTAL): V419 + RotaTeq + Prevenar 13 + ProQuad
- INFANRIX™ hexa (Type: ACTIVE_COMPARATOR): INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mantram Repetition Meditation for Veterans With PTSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Read and write English fluently~* Traumatic event related to military-duty, including combat, military training accidents, and military sexual trauma~* Transportation to attend meetings and available to complete study protocols~* Stable dose and type of PTSD medications for at least 6 weeks (per chart review)~* Willing to track medication changes during study~Exclusion Criteria:~* Inability to give informed, voluntary consent~* Cognitive impairment sufficient to cause inability to complete the protocol~* Psychotic symptoms~* Dementia or other organic mental disorders that may cause inability to complete the protocol~* Significant documented alcohol/substance abuse~* Presence of severe suicidal urges or intent~* Residence in a geographical area outside of San Diego County or Bedford, Massachusetts area~* Current daily practice of any skills of any meditation-based program - including, but not limited to:~  * Transcendental Meditation (TM)~ * Yoga~ * Tai Chi~ * Qi-Gong~ * Vipassana or Insight Meditation~ * Loving-Kindness or Compassion Meditation~ * Mindfulness-Based Stress Reduction (MBSR) or other mindfulness program~ * Guided Imagery~ * Mantram Repetition~ * Passage Meditation~ * Walking Meditation~ * Zen or Buddhist meditation~ * Self-hypnosis, Bio-feedback, etc.~* Other participant circumstances that, in the opinion of a consensus of the study team, would interfere with the safety of prospective participants or their need for treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mantram Repetition Program (MRP) (Type: EXPERIMENTAL): A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma.
- Present Centered Therapy (PCT) (Type: ACTIVE_COMPARATOR): Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for elective or urgent percutaneous coronary intervention with an FDA-approved device~* Having a target artery (native or graft) stenosis of 60% by visual estimation~Exclusion Criteria:~* Patients with unstable angina/non-Q-wave myocardial infarction meeting EPIC criteria within the previous 24 hours, or with acute Q-wave myocardial infarction meeting EPIC criteria with onset of chest pain within previous 24 hours~* With active internal bleeding, having a condition that may increase the risk of bleeding, or currently receiving administration of oral anticoagulants at the time of study entry~* With confirmed hypertension with systolic blood pressure \>180 mm Hg or diastolic blood pressure \>100 mm Hg~* Having had a percutaneous coronary intervention within the previous 3 months~* Having an unprotected left main coronary artery stenosis \> 50%

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo and Standard Dose of Heparin (Type: PLACEBO_COMPARATOR): Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
- Abciximab and Low Dose of Heparin (Type: ACTIVE_COMPARATOR): Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
- Abciximab and Standard Dose Heparin (Type: ACTIVE_COMPARATOR): Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for cataract surgery~Exclusion Criteria:~* Known hypersensitivity to bromfenac and salicylates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bromfenac (Type: EXPERIMENTAL): Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, dosed 1 drop daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete